KONEXBiotech & Pharma270210

SR biotek

₩11,990▲ 0.08%2026-10-02 close

Market Cap

₩20.5B

Turnover

₩486,340

Volume

44 shares

Shares out.

1.7M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Post-Turnaround Growth Sustainability in Focus

SR Biotech achieved a 260% revenue surge and full profitability turnaround in 2024, but the sustainability of that momentum remains the central question amid ultra-small scale, near-zero liquidity, and a thin equity cushion.

1
FY2024 revenue of KRW 29.5bn (+260% YoY), with operating profit of KRW 2.0bn and net profit of KRW 1.6bn — full profitability turnaround
2
Proprietary Altum nano-peptide technology — dermal-layer absorption enhancement patent — underpins brand differentiation
3
Strategic pivot from OEM/ODM to own-brand (IDENEL) professional line since H2 2023, targeting higher-margin channels
4
Formal entry into medical aesthetics B2B channels signaled by participation in KIMES 2026 (March 2026, COEX Seoul)
5
Ultra-thin liquidity (daily turnover ~KRW 882K), KONEX micro-cap status, and ~38-person workforce represent key structural constraints

Business structure

SR Biotech was established in May 2007 in Seongnam, Gyeonggi-do and listed on the KONEX market in 2017, specializing in cosmetics biomaterial development, manufacturing, and distribution.

Its core IP is the Altum platform — a nano-technology-based skin-barrier bypass patent that significantly enhances dermal absorption of cosmetic active ingredients — commercialized with Altum Peptide in March 2021 and expanded to Altum Collagen and Altum Biotin.

Products are sold under the proprietary brands IDENEL and Rapitox across domestic professional channels and international markets, with in-house R&D labs and a dedicated manufacturing facility.

The company holds ISO9001, ISO14001, and ISO22716 certifications alongside a venture firm designation, supporting seven registered patents and six active government-funded R&D projects.

In December 2019, SR Biotech was acquired and incorporated as a subsidiary of B2Link, an IT-driven K-beauty global distribution platform, providing structural access to overseas sales networks.

The H2 2023 strategic pivot away from low-margin OEM/ODM toward a concentrated own-brand professional-channel model marked a key inflection in its margin structure. Participation in KIMES 2026 (March 2026, COEX Seoul) formally signaled the company's intent to enter the medical aesthetics B2B segment.

Competition comes primarily from functional cosmetic material specialists such as CaraGEN, ExoCoBio, and FullcoSkin, with SR Biotech seeking differentiation via its Altum technology IP in the anti-aging and skin regeneration segment.

With roughly 38 employees as of end-2025, the lean organization allows agile decision-making while concentrating key-person risk.

Recent trends

SR Biotech remained in consecutive deficit through 2023. On a standalone basis, operating losses widened 65.4% year-on-year in 2023, net losses expanded 59.5%, and total equity turned negative (KRW -1.35bn), placing the company in full capital impairment.

A dramatic reversal, however, materialized in the first half of 2024: per media reports (Presto Stock News, August 2024), H1 2024 revenue reached KRW 17.0bn — exceeding the entire FY2023 revenue by 108% — with operating profit of KRW 852mn and net profit of KRW 659mn.

Full-year 2024 results (Presto Stock News, April 2025) confirmed revenue of KRW 29.4bn (+260.2% YoY), operating profit of KRW 2.03bn, and net profit of KRW 1.65bn, constituting a complete earnings turnaround.

Total liabilities fell 20.7% to KRW 4.24bn, while total equity rebounded to KRW 2.18bn, fully resolving the prior capital impairment. A rights offering in 2024 raised approximately KRW 1.9bn, and cash and equivalents stood at KRW 3.37bn at H1 2024 year-end.

On the market, the stock surged 701% during 2024 from KRW 3,495 to KRW 28,000 and subsequently extended to a record of around KRW 46,000.

As of June 7, 2026, the current price of KRW 13,360 represents an approximately 71% decline from that peak, with daily trading turnover at a near-zero KRW 882,130 — reflecting extreme illiquidity for a micro-cap KONEX listing.

Outlook

SR Biotech's near-term priority is demonstrating that the 2024 profitability turnaround is structurally durable. Deeper penetration of the IDENEL professional skincare line into expert channels should sustain higher unit margins compared with the former OEM/ODM model.

The formal entry into medical aesthetics — signaled by KIMES 2026 participation in March 2026 — opens a potential B2B pipeline targeting dermatology clinics and aesthetic medicine practices as a medium-term growth engine.

Globally, continued K-beauty demand momentum and a growing anti-aging skincare market provide a tailwind for overseas rollout of Altum peptide-based products. Leveraging parent company B2Link's IT-driven global K-beauty distribution infrastructure could meaningfully accelerate B2C channel diversification overseas.

The company's patented Altum technology portfolio also carries latent value through potential out-licensing or technology transfer, though no confirmed transactions have been publicly disclosed to date.

Declining headcount (approximately -7% MoM as of end-2025) and razor-thin market liquidity remain binding operational constraints, and any reliance on repeated equity offerings to fund growth would carry meaningful dilution risk for existing shareholders.

Bull factors

Structural Validity of the Earnings Reversal

FY2024 revenue of KRW 29.4bn (+260% YoY), operating profit of KRW 2.0bn, and net profit of KRW 1.6bn reflect a genuine structural shift in the P&L from the pivot to premium own-brand distribution — not an isolated one-off.

The fact that H1 2024 alone exceeded all of FY2023 revenue by 108% indicates momentum that outpaced initial expectations. Restoring total equity to a positive KRW 2.18bn — fully resolving prior capital impairment — marks concrete financial rehabilitation. A 20.7% debt reduction and KRW 3.37bn cash position partially address near-term liquidity concerns.

Differentiated IP Value in Altum Technology

The Altum peptide — a patented nano-technology that enhances dermal-layer penetration of cosmetic actives — is directly aligned with the growing adoption of science-backed cosmetics in clinical channels.

The platform's extensibility (Altum Collagen, Altum Biotin) supports incremental product line expansion and revenue diversification beyond the initial peptide application.

In the context of a growing global anti-aging skincare market, ingredient absorption-efficiency technology provides a credible basis for premium channel positioning. Six active government R&D grants partially offset technology development costs, reducing the internal R&D cash burden.

Medical Aesthetics Channel Expansion Optionality

Formalized at KIMES 2026, the medical aesthetics market entry adds a professional B2B distribution layer — dermatology, plastic surgery, and aesthetic clinics — alongside the existing consumer channel.

The global post-procedure recovery and skincare management market is a rapidly growing segment where Altum technology-based regenerative cosmetics can be positioned.

Professional channels typically command higher average selling prices and stronger repeat-purchase rates versus mass retail, making successful adoption potentially accretive to overall margin structure. Parent company B2Link's global network could lower the cost of entry into overseas clinical channels.

Bear factors

Extreme Illiquidity and Micro-Cap Structural Disadvantage

Daily trading turnover of KRW 882,130 (as of June 7, 2026) reflects a virtual absence of market liquidity, effectively preventing normal price-discovery mechanisms. The KONEX micro-cap designation limits access for institutional and foreign investors, compounding the liquidity discount.

The extreme price trajectory — from KRW 3,495 to ~KRW 46,000 and back to KRW 13,360 within roughly eighteen months — illustrates how thin liquidity amplifies speculative volatility disconnected from fundamentals.

In such an environment, execution costs are elevated, bid-ask spreads wide, and orderly position building or liquidation is practically impossible for any meaningful capital size.

Thin Financial Base and Limited Capital Buffer

Total equity of KRW 2.18bn at end-2024, while marking an exit from full capital impairment, remains an extremely thin buffer for even modest business scaling. Should further equity issuance be required to fund growth ambitions, existing shareholders face meaningful dilution risk.

Given the KRW 1.9bn rights offering already completed in 2024, the likelihood of recurrent external capital needs cannot be dismissed. The debt-to-equity ratio — total liabilities of KRW 4.24bn against total equity of KRW 2.18bn — still implies limited additional borrowing capacity, narrowing financing options.

Workforce Contraction and Organizational Execution Risk

A workforce decline to approximately 38 employees as of end-2025 — down 7% month-on-month — suggests organizational capacity may be shrinking at a time when the company is attempting to accelerate growth.

In a small-team environment, the departure of key personnel in R&D, sales, or manufacturing can produce immediate functional disruptions with limited redundancy to absorb the loss.

Simultaneously pursuing new verticals in medical aesthetics and international channels requires incremental human capital investment, directly conflicting with the observed headcount contraction trend.

Limited public disclosure of personnel and organizational data further prevents external observers from accurately assessing execution capacity.

Risk factors

Macro & Industry Risk

A global economic slowdown or deterioration in consumer confidence would directly pressure sales of premium functional cosmetics, SR Biotech's core offering.

Despite the K-beauty tailwind, competitive intensity among domestic cosmetics brands and ODM producers is rising, making shelf and channel access harder for smaller brands with limited marketing budgets.

Currency fluctuations represent a two-way risk — affecting both the cost of imported raw materials and export revenue margins. Given the company's scale disadvantage versus larger peers, revenue trajectory is highly sensitive to overall sector conditions.

Regulatory & Compliance Risk

Expansion into medical aesthetics channels may trigger additional regulatory requirements related to quasi-pharmaceutical or medical device classifications, imposing licensing costs and approval timelines.

Tightening global cosmetics ingredient regulations could require additional safety substantiation for Altum-related novel materials, creating potential compliance cost overruns.

Overseas market entry — particularly under the EU Cosmetics Regulation and US FDA frameworks — involves country-specific regulatory barriers that can delay market launch schedules and inflate entry costs.

Given the company's lean workforce, limited dedicated regulatory compliance personnel heightens the risk of schedule delays when navigating such frameworks.

Liquidity & Governance Risk

KONEX-listed companies operate under lighter disclosure and corporate governance obligations than KOSPI/KOSDAQ peers, creating a structural information asymmetry for outside investors.

Extreme illiquidity means that in a period of adverse sentiment, exit options for investors are effectively unavailable — magnifying downside risk.

The opacity of intra-group transactions and subsidiary relationships with parent B2Link may create unverified potential conflicts of interest that are structurally difficult for minority shareholders to monitor.

Recurrent equity issuance, structurally more likely for small firms with limited retained earnings, remains an ongoing dilution risk that investors must factor into long-term holding decisions.

Overall view

SR Biotech delivered a materially validated 2024 earnings recovery — a 260% revenue surge and full profitability restoration — reflecting early tangible results from the H2 2023 own-brand strategic pivot.

The Altum technology platform and nascent medical aesthetics channel push provide credible narrative anchors for a medium-term growth thesis. Nevertheless, the KONEX micro-cap structure and near-zero daily liquidity (KRW 882K) fundamentally undermine market price integrity independent of operating performance.

A thin total equity cushion of KRW 2.18bn, declining headcount, and limited public disclosure visibility reinforce a structurally cautious stance.

The stock has already corrected approximately 71% from its KRW 46,000 peak to KRW 13,360, suggesting a significant portion of the turnaround narrative was rapidly priced in and then fully reversed — but with no reliable liquidity mechanism, fair value remains difficult to anchor.

This report maintains a Neutral stance, with consecutive post-2024 earnings confirmation, liquidity environment improvement, and tangible medical aesthetics revenue contribution as the primary triggers for potential reassessment.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 6 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.